DiaSorin S.p.A

DiaSorin S.p.A was founded in 1968 in Italy and has its headquarters in Saluggia, a small town in the province of Vercelli. The company specializes in the immunodiagnostics and molecular diagnostics segments, which are used to detect and measure specific molecules or antigens in biological samples.

The company has a wide range of products and projects that cover various clinical areas, such as infectious diseases, endocrinology, oncology, autoimmunity, bone and mineral metabolism, and cardiovascular diseases. Some of their most innovative products include LIAISON ® XS, a fully automated system for immunochemistry tests, and LIAISON ® MDX, a platform for molecular diagnostics based on real-time PCR technology.

DiaSorin S.p.A has a strong presence in the global market, with 22 branches and offices across 5 continents and 5 manufacturing sites around the world. The company has a market cap of about $7.6B as of May 2023 and employs more than 2,000 people worldwide.

The vision of DiaSorin S.p.A is to be the diagnostic specialist that provides reliable, innovative, and standardized solutions for clinical laboratories and patients. The company is committed to investing in research and development, using its distinctive expertise in the field to deliver a high level of innovation. The company has also received several awards and recognitions for its excellence in quality, sustainability, and social responsibility.

Foundation: 1968

Headquarters: Saluggia, Vercelli, Italy

Website: https://www.diasorin.com/home/